法匹拉韋|Favipiravir|259793-96-9|MFCD16879084-范德生物科技公司

法匹拉韋

法匹拉韋
NMR and HPLC COA下載 MSDS下載
Names：
Favipiravir
CAS號：
259793-96-9
MDL Number： MFCD16879084
MF(分子式)： C5H4FN3O2 MW(分子量)： 157.0287545
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

法匹拉韋（Favipiravir,259793-96-9）是一種吡嗪甲酰胺衍生物，Favipiravir具有抗RNA病毒活性。Favipiravir 通過宿主酶轉化為呋喃三磷酸核糖酯衍生物，可以選擇性地抑制流感病毒RNA依賴的RNA聚合酶。

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
HCQ000001-1g	1g	98%	￥ 1200.00	￥ 1200.00		instock	- +	￥ 0.00
HCQ000001-100mg	100mg	98%	￥ 580.00	￥ 580.00		instock	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	法維拉韋;法匹沙韋;法匹拉韋（CAS:259793-96-9,MSDS,應用,溶解度,）,法匹拉韋雜質
英文別名	Favipiravir,259793-96-9,Favipiravir (T-705),T 705,T-705,T705
CAS號	259793-96-9
SMILES	NC(=O)C1=NC(F)=CN=C1O
Inchi	InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3
InchiKey	KCFYEAOKVJSACF-UHFFFAOYSA-N
分子式 Molecular Weight	C5H4FN3O2
分子量 Formula	157.0287545
閃點 FP	311.7±30.1 °C
熔點 Melting point	187℃ to 193℃
沸點 Boiling point	591.8±50.0 °C at 760 mmHg
Polarizability極化度	48.3±0.5 10-24cm3
密度 Density	1.6±0.1 g/cm3
蒸汽壓 Vapor Pressure	0.0±1.7 mmHg at 25°C
溶解度Solubility	8.7 mg/mL，slightly soluble in water
性狀	固體粉末
儲藏條件 Storage conditions	Store at room temperature

法匹拉韋（CAS:259793-96-9,英文名:favipiravir）Protocol:

法匹拉韋細胞實驗
Cell lines	MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells
Preparation method	The cytotoxicity of T-705 is evaluated by an assay with XTT. XTT is converted to aqueous formazan by an enzyme in MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells. The compounds are diluted to the appropriate concentrations (volume, 100 μl) with test medium (EMEM containing 10% FCS) in 96-well culture plates in which each well contains a concentration of 2 × 103 cells/100 μL. The test plates are incubated for 3 days at 37°C in 100% humidity and 5% CO2. After 3 days, 50 μl of the XTT reagent (1 mg/ml in FCS-free EMEM containing 5 mM phenazine methosulfate) is added, and the reaction product is assayed by measurement of the absorbance at 450 nm with a microplate reader. Cytotoxicity is expressed as the 50% cell-inhibitory concentration (CC50).
Concentrations	1000 μg/mL
Incubation time	3 d

法匹拉韋動物實驗
Animal models	Mice infected with influenza virus A/PR/8/34
Formulation	0.5% methylcellulose
Dosages	200 mg/kg/day
Administration	p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

Species	Mouse	Rat	Rabbit	Guinea pig	Hamster	Dog
Weight (kg)	0.02	0.15	1.8	0.4	0.08	10
Body Surface Area (m²)	0.007	0.025	0.15	0.05	0.02	0.5
K_m factor	3	6	12	8	5	20

Animal A (mg/kg) = Animal B (mg/kg) multiplied by	Animal B K_m
	Animal A K_m

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the K_m factor for a mouse and then divide by the K_m factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Tags:法匹拉韋試劑,法匹拉韋抑制劑,法匹拉韋衍生物,法匹拉韋磷酸鹽衍生物,法匹拉韋雜質,法匹拉韋中間體,法匹拉韋公司,法匹拉韋購買;法匹拉韋供應商,

產品說明	法匹拉韋（259793-96-9,favipiravir）5-羥基-法匹拉韋,法匹拉韋一磷酸,法匹拉韋二磷酸,法匹拉韋三磷酸均為有效的病毒抑制劑
Introduction	Favipiravir（259793-96-9）Favipiraviris triphosphate are initially approved for therapeutic use in resistant cases of influenza.7,9 The antiviral targets RNA-dependent RNA polymerase (RdRp) enzymes.
Application1	潛在冠狀病毒抑制劑Experimental Unapproved Treatments for COVID-19,may be an alternative option for influenza strains that are resistant to neuramidase inhibitors.9,19
Application2	法匹拉韋在人體內通過與糖作用生成“SCHEMBL7215591”，之后在結合磷酸鹽生成法匹拉韋三磷酸形式產物，最終對病毒產生作用。
Application3	Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.10,14,15

法匹拉韋（CAS:259793-96-9,英文名:favipiravir）不僅可以抑制甲型和乙型流感病毒的復制，而且該藥在禽流感的治療中也有不錯的療效，并且可能是對神經酰胺酶抑制劑有抗藥性的流感菌株的替代選擇?？梢宰鳛橹委熗{生命的病原體，例如埃博拉病毒，拉沙病毒和現在的COVID-19

Favipiravir作為前藥起作用，并在細胞內進行核糖基化和磷酸化，成為活性的Favipiravir-RTP。Favipiravir-RTP結合并抑制RNA依賴性RNA聚合酶（RdRp），最終可以阻止病毒轉錄和復制。

與現有的流感抗病毒藥相比，favipiravir的作用機制是新穎的，主要能阻止病毒從細胞中進入和退出?；钚缘膄avipiravir-RTP選擇性抑制RNA聚合酶并阻止病毒基因組的復制。目前有幾種假設favipiravir-RTP如何與RNA依賴性RNA聚合酶（RdRp）相互作用。一些研究表明，將favipiravir-RTP摻入新生的RNA鏈中時，它會阻止RNA鏈延長和病毒增殖。7研究還發現，嘌呤類似物可以降低favipiravir的抗病毒活性，表明favipiravir-RTP和嘌呤核苷之間存在RdRp結合競爭7。
盡管favipiravir最初是開發用于治療流感的，但預計RdRp催化域（favipiravir的主要靶標）與其他RNA病毒相似。這種保守的RdRp催化域有助于favipiravir的廣譜覆蓋。

transcription of virus RNA segments. The transcription of viral mRNAs occurs by a unique mechanism called cap-snatching. 5' methylated caps of cellular mRNAs are cleaved after 10-13 nucleotides by PA. In turn, these short capped RNAs are used as primers by PB1 for transcription of viral mRNAs. During virus replication, PB1 initiates RNA synthesis and copy vRNA into complementary RNA (cRNA) which in turn serves as a template for the production of more vRNAs.Favipiravir shows anti-influenza virus activities with IC50 ranged from 0.013 to 0.48 μg/ml for the influenza A viruses, from 0.039 to 0.089 μg/ml for the influenza B viruses, and from 0.030 to 0.057 μg/ml for the influenza C viruses. In mammalian cell lines (MDCK cells, Vero cells, HEL cells, A549 cells, HeLa cells, and HEp-2 cells), Favipiravir shows no cytotoxicity at concentrations up to 1,000 μg/ml. In MDCK cells inoculated with seasonal influenza A (H1N1) viruses, Favipiravir induces lethal mutagenesis.

警示圖
危險性
危險性警示	Based on single-dose toxicity studies, the lethal dose for oral and intravenous favipiravir in mice is estimated to be >2000 mg/kg.18 In rats, the lethal dose for oral administration is >2000 mg/kg, while the lethal dose in dogs and monkeys is >1000 mg/kg.18 Symptoms of overdose appear to include but are not limited to reduced body weight, vomiting, and decreased locomotor activity.18
安全聲明	H332; H403
安全防護	P332+P313; P305+P351+P338實驗過程防止食如、吸入
備注	NA

In repeat-dose toxicity studies involving dogs, rats, and monkeys, notable findings after administration of oral favipiravir included: adverse effects on hematopoietic tissues such as decreased red blood cell (RBC) production, and increases in liver function parameters such as aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine aminotransferase (ALT) and total bilirubin, and increased vacuolization in hepatocytes.18 Testis toxicity was also noted.18 Favipiravir is known to be teratogenic; therefore, administration of favipiravir should be avoided in women if pregnancy is confirmed or suspected.7,16 Toxicity information regarding favipiravir in humans is not readily available.

Hsieh HP, Hsu JT: Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42. [PubMed:18220789]

Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwell RW: In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother. 2007 Sep;51(9):3168-76. Epub 2007 Jul 2. [PubMed:17606691]

Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, Wong MH, Morrey JD, Furuta Y: Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother. 2007 Mar;51(3):845-51. Epub 2006 Dec 28. [PubMed:17194832]

Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, Nomura N, Egawa H, Shiraki K: Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005 Mar;49(3):981-6. [PubMed:15728892]

Beigel J, Bray M: Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. doi: 10.1016/j.antiviral.2008.01.003. Epub 2008 Feb 4.

Beigel J, Bray M: Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008 Apr;78(1):91-102. doi: 10.1016/j.antiviral.2008.01.003. Epub 2008 Feb 4.
Hsieh HP, Hsu JT: Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42.

Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K: In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002 Apr;46(4):977-81.
Furuta Y, Komeno T, Nakamura T: Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463. doi: 10.2183/pjab.93.027.

Venkataraman S, Prasad BVLS, Selvarajan R: RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution. Viruses. 2018 Feb 10;10(2). pii: v10020076. doi: 10.3390/v10020076.

Hayden FG, Shindo N: Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019 Apr;32(2):176-186. doi: 10.1097/QCO.0000000000000532.

Madelain V, Nguyen TH, Olivo A, de Lamballerie X, Guedj J, Taburet AM, Mentre F: Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clin Pharmacokinet. 2016 Aug;55(8):907-23. doi: 10.1007/s40262-015-0364-1.

Nguyen TH, Guedj J, Anglaret X, Laouenan C, Madelain V, Taburet AM, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentre F: Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017 Feb 23;11(2):e0005389. doi: 10.1371/journal.pntd.0005389. eCollection 2017 Feb.

de Farias ST, Dos Santos Junior AP, Rego TG, Jose MV: Origin and Evolution of RNA-Dependent RNA Polymerase. Front Genet. 2017 Sep 20;8:125. doi: 10.3389/fgene.2017.00125. eCollection 2017.

Shu B, Gong P: Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation. Proc Natl Acad Sci U S A. 2016 Jul 12;113(28):E4005-14. doi: 10.1073/pnas.1602591113. Epub 2016 Jun 23.

Nagata T, Lefor AK, Hasegawa M, Ishii M: Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep. 2015 Feb;9(1):79-81. doi: 10.1017/dmp.2014.151. Epub 2014 Dec 29.

Rosenke K, Feldmann H, Westover JB, Hanley PW, Martellaro C, Feldmann F, Saturday G, Lovaglio J, Scott DP, Furuta Y, Komeno T, Gowen BB, Safronetz D: Use of Favipiravir to Treat Lassa Virus Infection in Macaques. Emerg Infect Dis. 2018 Sep;24(9):1696-1699. doi: 10.3201/eid2409.180233. Epub 2018 Sep 17.

Delang L, Abdelnabi R, Neyts J: Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018 May;153:85-94. doi: 10.1016/j.antiviral.2018.03.003. Epub 2018 Mar 7.

Nature Biotechnology: Coronavirus puts drug repurposing on the fast track

Pharmaceuticals and Medical Devices Agency: Avigan (favipiravir) Review Report

World Health Organization: Influenza (Avian and other zoonotic)

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開

相關產品
< >

推薦產品
< >

最新產品
< >

新聞

牛血清白蛋白（BSA）常見問題

牛血清白蛋白（BSA）常見問題:牛血清白蛋白（BSA）在實驗室中是通用的，可用于蛋白質印跡、細胞組織培養、P...

2022/10/19 9:39:51

pubmed使用方法(技巧)

pubmed使用方法(技巧)：PubMed是一個關于醫學問題的學術文章和書籍的數據庫。因為它是一份學術期刊，...

2022/10/18 18:06:07

BSA(牛血清白蛋白)

BSA(牛血清白蛋白):牛血清白蛋白（BSA）是一種球狀蛋白質，牛血清白蛋白（BSA）是發現于牛血漿中的主要...

2022/10/18 16:48:12

凍干培養細菌的方法

凍干培養細菌的方法：冷凍干燥，也稱為凍干或冷凍干燥，是在產品冷凍后除去水分并將其置于真空中的過程。這使得冰可...

2022/10/16 8:27:31

革蘭氏染色應用(原理,方法,步驟,優缺點)

微生物中的革蘭氏染色應用：革蘭氏染色是一種差異染色方法，用于根據細菌細胞壁的特性將細菌分為兩組（革蘭氏陽性和...

2022/10/16 8:10:57

支原體去除劑的使用方法,工作濃度,對細胞有影響嗎？

支原體去除劑的使用方法,工作濃度,對細胞有影響嗎？將支原體清除劑添加到被支原體污染的細胞培養物中，濃度建議為...

2022/10/13 9:24:46

DNA和染色體之間的差別

DNA和染色體之間的差別：DNA和染色體的關鍵區別在于其結構的組織。DNA是由脫氧核糖核苷酸組成的雙鏈螺旋聚...

2022/10/10 12:49:53

DNA分離和RNA分離的區別

DNA分離和RNA分離的區別:DNA和RNA分離的關鍵區別在于，DNA分離是從生物細胞中提取一種稱為DNA的...

2022/10/8 15:22:57

PMSF蛋白酶抑制劑使用中的常見問題

PMSF蛋白酶抑制劑使用中的常見問題:

2022/10/1 7:48:57

PMSF（苯甲基磺酰氟）

PMSF（苯甲基磺酰氟）：PMSF（苯甲基磺酰氟）是一種不可逆的絲氨酸蛋白酶抑制劑，用于各種研究和實驗室過程...

2022/9/30 22:18:04

法匹拉韋

法匹拉韋

Favipiravir

259793-96-9

快速詢價

你想詢價的產品

請準確填寫您的聯系方式，以便為您提供最好的服務。

新聞

牛血清白蛋白（BSA）常見問題

pubmed使用方法(技巧)

BSA(牛血清白蛋白)

凍干培養細菌的方法

革蘭氏染色應用(原理,方法,步驟,優缺點)

支原體去除劑的使用方法,工作濃度,對細胞有影響嗎？

DNA和染色體之間的差別

DNA分離和RNA分離的區別

PMSF蛋白酶抑制劑使用中的常見問題

PMSF（苯甲基磺酰氟）

請準確填寫您的聯系方式，以便為您提供最好的服務。

支原體去除劑的使用方法,工作濃度,對細胞有影響嗎？